8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 31, 2026·SEC
Palvella Therapeutics, Inc.(PVLA)Earnings, Financials & Key Ratios
PVLA•NASDAQ
$130.17
$1.54B mkt cap·Price updated May 6, 2026
AboutPalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.Show more
- Revenue$0
- EBITDA-$36M-173.7%
- Net Income-$42M-139.3%
- EPS (Diluted)-3.71+52.6%
- ROE-92.1%-55.1%
- Debt/Equity0.02
- Interest Coverage-6.17-103.1%
PVLA Key Insights
Palvella Therapeutics, Inc. (PVLA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 88 (top 12%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
- ✗Expensive at 52.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PVLA Price & Volume
Palvella Therapeutics, Inc. (PVLA) stock price & volume — 10-year historical chart
Loading chart...
PVLA Growth Metrics
Palvella Therapeutics, Inc. (PVLA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-173.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.23%
Return on Capital
10 Years-68.9%
5 Years-74.49%
3 Years-81.9%
Last Year-62.06%
PVLA Recent Earnings
Palvella Therapeutics, Inc. (PVLA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (50%)
Q2 2026Latest
Mar 31, 2026EPS
$1.08
Est $0.91
-18.5%
Revenue
—
Q4 2025
Nov 11, 2025EPS
$1.03
Est $0.85
-21.2%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.86
Est $0.78
-10.3%
Revenue
—
Q2 2025
May 15, 2025EPS
$0.74
Est $3.40
+78.2%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $1.08vs $0.91-18.5% | — |
| Q4 2025 | Nov 11, 2025 | $1.03vs $0.85-21.2% | — |
| Q3 2025 | Aug 14, 2025 | $0.86vs $0.78-10.3% | — |
| Q2 2025 | May 15, 2025 | $0.74vs $3.40+78.2% | — |
Based on last 12 quarters of dataView full earnings history →
PVLA Peer Comparison
Palvella Therapeutics, Inc. (PVLA) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 |
Compare PVLA vs Peers
Palvella Therapeutics, Inc. (PVLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PVLA Income Statement
Palvella Therapeutics, Inc. (PVLA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Sales/Revenue | 29.32M | 31.42M | 25.9M | 0 | 0 | 0 |
| Revenue Growth % | - | - | -17.56% | -100% | - | - |
| Cost of Goods Sold | 0 | 2.37M | 2.78M | 0 | 0 | 0 |
| COGS % of Revenue | - | 7.54% | 10.73% | - | - | - |
| Gross Profit | 29.32M▲ 0% | 29.05M▼ 0.9% | 23.12M▼ 20.4% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | 100% | 92.46% | 89.27% | - | - | - |
| Gross Profit Growth % | - | - | -20.41% | -100% | - | - |
| Operating Expenses | 61.12M | 80.88M | 66.6M | 11.87M | 14.1M | 38.6M |
| OpEx % of Revenue | 208.43% | 257.44% | 257.11% | - | - | - |
| Selling, General & Admin | 16.9M | 16.68M | 16.38M | 3.08M | 5.94M | 15.76M |
| SG&A % of Revenue | 57.62% | 53.1% | 63.25% | - | - | - |
| Research & Development | 44.22M | 64.2M | 50.21M | 8.79M | 8.15M | 22.84M |
| R&D % of Revenue | 150.8% | 204.33% | 193.85% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -33.92M▲ 0% | -51.83M▼ 52.8% | -43.47M▲ 16.1% | -11.87M▲ 72.7% | -14.1M▼ 18.8% | -38.6M▼ 173.9% |
| Operating Margin % | -115.68% | -164.97% | -167.84% | - | - | - |
| Operating Income Growth % | - | - | 16.12% | 72.7% | -18.75% | -173.87% |
| EBITDA | -31.79M | -49.46M | -40.69M | 18.69M | -13.12M | -35.9M |
| EBITDA Margin % | -108.43% | -157.44% | -157.11% | - | - | - |
| EBITDA Growth % | - | - | 17.73% | 145.93% | -170.18% | -173.67% |
| D&A (Non-Cash Add-back) | 2.13M | 2.37M | 2.78M | 0 | 0 | 0 |
| EBIT | -37.07M | -45.74M | -33.28M | 18.69M | -13.12M | -35.9M |
| Net Interest Income | 511K | 4K | 721K | 6.26M | -4.32M | -3.23M |
| Interest Income | 511K | 4K | 721K | 6.26M | 0 | 2.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 4.32M | 5.82M |
| Other Income/Expense | -3.15M | 6.09M | 10.2M | 30.56M | -3.34M | -3.11M |
| Pretax Income | -37.07M▲ 0% | -45.74M▼ 23.4% | -33.28M▲ 27.2% | 18.69M▲ 156.2% | -17.43M▼ 193.3% | -41.72M▼ 139.3% |
| Pretax Margin % | -126.41% | -145.58% | -128.47% | - | - | - |
| Income Tax | 164K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.44% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -37.23M▲ 0% | -45.74M▼ 22.9% | -33.28M▲ 27.2% | 18.69M▲ 156.2% | -17.43M▼ 193.3% | -41.72M▼ 139.3% |
| Net Margin % | -126.97% | -145.58% | -128.47% | - | - | - |
| Net Income Growth % | - | - | 27.24% | 156.17% | -193.27% | -139.27% |
| Net Income (Continuing) | -37.23M | -45.74M | -33.28M | 18.69M | -17.43M | -41.72M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -54.67▲ 0% | -56.69▼ 3.7% | -29.61▲ 47.8% | 14.74▲ 149.8% | -7.83▼ 153.1% | -3.71▲ 52.6% |
| EPS Growth % | - | - | 47.77% | 149.78% | -153.12% | 52.62% |
| EPS (Basic) | -54.67 | -56.69 | -29.61 | 14.74 | -7.83 | -3.71 |
| Diluted Shares Outstanding | 681.01K | 806.84K | 930.35K | 1.27M | 2.23M | 11.25M |
| Basic Shares Outstanding | 681.01K | 806.84K | 930.35K | 1.27M | 2.23M | 11.25M |
| Dividend Payout Ratio | - | - | - | - | - | - |
PVLA Balance Sheet
Palvella Therapeutics, Inc. (PVLA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Total Current Assets | 75.72M | 127.63M | 16.52M | 7.55M | 88.23M | 58.99M |
| Cash & Short-Term Investments | 70.44M | 117.76M | 16.05M | 7.35M | 83.6M | 57.98M |
| Cash Only | 70.44M | 117.76M | 16.05M | 7.35M | 83.6M | 57.98M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.71M | 3.31M | 0 | 0 | 2.34M | 0 |
| Days Sales Outstanding | 21.24 | 38.49 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 3.58M | 6.55M | 471K | 198K | 2.3M | 1M |
| Total Non-Current Assets | 29.29M | 25.93M | 0 | 0 | 0 | 572K |
| Property, Plant & Equipment | 25.98M | 23.03M | 0 | 0 | 0 | 572K |
| Fixed Asset Turnover | 1.13x | 1.36x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.31M | 2.9M | 0 | 0 | 0 | 0 |
| Total Assets | 105.01M▲ 0% | 153.56M▲ 46.2% | 16.52M▼ 89.2% | 7.55M▼ 54.3% | 88.23M▲ 1069.0% | 59.56M▼ 32.5% |
| Asset Turnover | 0.28x | 0.20x | 1.57x | - | - | - |
| Asset Growth % | - | - | -89.24% | -54.32% | 1068.97% | -32.5% |
| Total Current Liabilities | 22.14M | 50.56M | 5.78M | 2.36M | 12.04M | 11.34M |
| Accounts Payable | 1.79M | 8.61M | 3.18M | 936K | 4.59M | 4.59M |
| Days Payables Outstanding | - | 1.33K | 417.65 | - | - | - |
| Short-Term Debt | 1.03M | 1.05M | 0 | 0 | 0 | 202K |
| Deferred Revenue (Current) | 12.63M | 25.12M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.94M | 12.21M | 921K | 344K | 6.24M | 6.55M |
| Current Ratio | 3.42x | 2.52x | 2.86x | 3.20x | 7.33x | 5.20x |
| Quick Ratio | 3.42x | 2.52x | 2.86x | 3.20x | 7.33x | 5.20x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 51.84M | 52.24M | 33.92M | 9.07M | 13.59M | 20.23M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 431K |
| Capital Lease Obligations | 15.93M | 13.84M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6K | 0 | 33.92M | 9.07M | 13.59M | 19.8M |
| Total Liabilities | 73.98M | 102.81M | 39.7M | 11.43M | 25.63M | 31.58M |
| Total Debt | 16.96M | 14.89M | 0 | 0 | 0 | 633K |
| Net Debt | -53.47M | -102.87M | -16.05M | -7.35M | -83.6M | -57.35M |
| Debt / Equity | 0.55x | 0.29x | - | - | - | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | -0.39x | - | - |
| Interest Coverage | - | - | - | - | -3.04x | -6.17x |
| Total Equity | 31.03M▲ 0% | 50.76M▲ 63.6% | -23.17M▼ 145.7% | -3.88M▲ 83.3% | 62.61M▲ 1713.6% | 27.98M▼ 55.3% |
| Equity Growth % | - | - | -145.66% | 83.26% | 1713.58% | -55.3% |
| Book Value per Share | 45.56 | 62.91 | -24.91 | -3.06 | 28.13 | 2.49 |
| Total Shareholders' Equity | 31.03M | 50.76M | -23.17M | -3.88M | 62.61M | 27.98M |
| Common Stock | 56K | 72K | 0 | 0 | 11K | 12K |
| Retained Earnings | -211.41M | -257.14M | -94.99M | -76.3M | -93.73M | -135.45M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -295K | 829K | 0 | 0 | 3K | 83K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
PVLA Cash Flow Statement
Palvella Therapeutics, Inc. (PVLA) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Cash from Operations | -45.9M | -7.66M | -14.84M | -13.7M | -10.84M | -25.01M |
| Operating CF Margin % | -156.52% | -24.38% | -57.29% | - | - | - |
| Operating CF Growth % | - | - | -93.73% | 7.66% | 20.89% | -130.68% |
| Net Income | -37.23M | -45.74M | -27.55M | 18.69M | -17.43M | -41.72M |
| Depreciation & Amortization | 2.13M | 2.37M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 427K | 603K | 830K | 6.4M |
| Deferred Taxes | 164K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.42M | 5.18M | 10.66M | -29.85M | 5.96M | 6.49M |
| Working Capital Changes | -16.38M | 30.52M | 1.62M | -3.15M | -193K | 3.82M |
| Change in Receivables | 5.34M | -1.81M | 0 | 0 | -1.98M | 2.49M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -4.35M | 7.05M | 1.98M | -2.25M | 2.24M | 1.26M |
| Cash from Investing | 39.21M | -949K | 0 | 0 | 0 | 0 |
| Capital Expenditures | -2.73M | -949K | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 9.3% | 3.02% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 10.12M | 59.13M | 9.57M | 5M | 87.09M | -660K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 78.43M | 0 |
| Equity Issued (Net) | 1000K | 59.13M | 9.53M | 0 | 0 | 763K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 34K | 5M | 8.65M | -1.42M |
| Net Change in Cash | 8.18M▲ 0% | 47.33M▲ 478.9% | -5.27M▼ 111.1% | -8.7M▼ 65.0% | 76.25M▲ 976.2% | -25.62M▼ 133.6% |
| Free Cash Flow | -48.62M▲ 0% | -8.61M▲ 82.3% | -14.84M▼ 72.4% | -13.7M▲ 7.7% | -10.84M▲ 20.9% | -25.01M▼ 130.7% |
| FCF Margin % | -165.82% | -27.4% | -57.29% | - | - | - |
| FCF Growth % | - | - | -72.38% | 7.66% | 20.89% | -130.68% |
| FCF per Share | -71.40 | -10.67 | -15.95 | -10.81 | -4.87 | -2.22 |
| FCF Conversion (FCF/Net Income) | 1.23x | 0.17x | 0.45x | -0.73x | 0.62x | 0.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
PVLA Key Ratios
Palvella Therapeutics, Inc. (PVLA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -119.99% | -90.12% | -241.3% | - | -59.37% | -92.1% |
| Gross Margin | 100% | 92.46% | 89.27% | - | - | - |
| Net Margin | -126.97% | -145.58% | -128.47% | - | - | - |
| Debt / Equity | 0.55x | 0.29x | - | - | - | 0.02x |
| Interest Coverage | - | - | - | - | -3.04x | -6.17x |
| FCF Conversion | 1.23x | 0.17x | 0.45x | -0.73x | 0.62x | 0.60x |
| Revenue Growth | - | - | -17.56% | -100% | - | - |
PVLA SEC Filings & Documents
Palvella Therapeutics, Inc. (PVLA) SEC filings — annual & quarterly reports (10-K, 10-Q)
PVLA Frequently Asked Questions
Palvella Therapeutics, Inc. (PVLA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Palvella Therapeutics, Inc. (PVLA) grew revenue by 0.0% over the past year. Growth has been modest.
Palvella Therapeutics, Inc. (PVLA) reported a net loss of $41.7M for fiscal year 2025.
Dividend & Returns
Palvella Therapeutics, Inc. (PVLA) has a return on equity (ROE) of -92.1%. Negative ROE indicates the company is unprofitable.
Palvella Therapeutics, Inc. (PVLA) had negative free cash flow of $25.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More PVLA
Palvella Therapeutics, Inc. (PVLA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates